

CytomX Therapeutics, Inc. Logo

## CytomX Therapeutics to Present at Upcoming March Investor Conferences

February 28, 2023 at 4:05 PM EST

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in the following investor conferences in March.

### **Cowen 43rd Annual Health Care Conference**

Date: Tuesday, March 7, 2023  
Panel Discussion: 9:10 a.m. ET  
Location: Boston, MA

### **Barclays Global Healthcare Conference**

Date: Tuesday, March 14, 2023  
Fireside Chat: 4:05 p.m. ET  
Location: Miami, FL

Live webcasts of the Cowen panel discussion and Barclays fireside chat will be available on the Events and Presentations page of CytomX's website at [www.cytomx.com](http://www.cytomx.com). In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.

### **About CytomX Therapeutics**

CytomX is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. By pioneering a novel class of conditionally activated biologics, powered by its Probody<sup>®</sup> technology platform, CytomX's goal is to transcend the limits of current cancer treatments. CytomX's robust and differentiated pipeline comprises five therapeutic candidates across multiple treatment modalities including antibody-drug conjugates ("ADCs"), T-cell engaging bispecific antibodies ("TCBs"), and immune modulators such as cytokines and checkpoint inhibitors ("CPIs"). CX-2029 is an investigational conditionally activated antibody-drug conjugate (ADC) directed toward CD71 and is being developed in collaboration with AbbVie. CytomX's clinical pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probody therapeutic BMS-986288, partnered with Bristol Myers Squibb, as well as CX-904, a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells, which is partnered with Amgen. In addition, CytomX has a diverse preclinical portfolio of wholly-owned assets including CX-801, an interferon alpha-2b Probody cytokine that has broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors and CX-2051, a conditionally activated ADC directed toward EpCAM, with potential applicability across multiple EpCAM-expressing epithelial cancers. CytomX has also established strategic collaborations with multiple leaders in oncology, including AbbVie, Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit [www.cytomx.com](http://www.cytomx.com) and follow us on [LinkedIn](#) and [Twitter](#).

Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.

### **CytomX Contact:**

Chris Ogden  
SVP, Finance and Accounting  
[cogden@cytomx.com](mailto:cogden@cytomx.com)  
(317) 767-4764

### **Investor and Media Contact:**

Stern Investor Relations  
Stephanie Ascher  
[stephanie.ascher@sternir.com](mailto:stephanie.ascher@sternir.com)  
212-362-1200



Source: CytomX Therapeutics Inc.